Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · IEX Real-Time Price · USD
4.290
-0.120 (-2.72%)
At close: Jun 11, 2024, 4:00 PM
4.510
+0.220 (5.13%)
After-hours: Jun 11, 2024, 4:50 PM EDT
Moleculin Biotech Stock Forecast
MBRX's stock price has decreased by -54.57% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Moleculin Biotech stock have an average target of 35, with a low estimate of 20 and a high estimate of 45. The average target predicts an increase of 715.85% from the current stock price of 4.29.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 12, 2024.
Analyst Ratings
The average analyst rating for MBRX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Roth MKM | Roth MKM | Strong Buy Maintains $40 | Strong Buy | Maintains | $40 | +832.40% | Apr 12, 2024 |
Maxim Group | Maxim Group | Strong Buy Maintains $45 → $20 | Strong Buy | Maintains | $45 → $20 | +366.20% | Mar 26, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +948.95% | Dec 14, 2023 |
Roth MKM | Roth MKM | Strong Buy Maintains $240 | Strong Buy | Maintains | $240 | +5,494.41% | Apr 18, 2023 |
Oppenheimer | Oppenheimer | Buy Reiterates $75 | Buy | Reiterates | $75 | +1,648.25% | Mar 24, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-8.31
from -15.07
EPS Next Year
-5.71
from -8.31
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 44.1M | 91.4M |
Avg | n/a | n/a | n/a | 33.3M | 75.6M |
Low | n/a | n/a | n/a | 15.5M | 50.9M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 174.4% |
Avg | - | - | - | - | 127.2% |
Low | - | - | - | - | 52.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -7.12 | -5.54 | -4.11 |
Avg | -8.31 | -5.71 | -4.47 |
Low | -9.33 | -5.80 | -4.75 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.